Diabetes complications and comorbidities: Cardiovascular disease

Add-on treatment with the SGLT1 and 2 inhibitor sotagliflozin may reduce cardiovascular risk among patients with type 2 diabetes and chronic kidney disease, suggest findings from the SCORED trial published in The New England Journal of Medicine.

Secondary analysis of the VERTIS CV trial supports a significant protective effect of ertugliflozin on risk for heart failure in people with type 2 diabetes, despite the overall neutral outcome of the trial.

A large study of data from people with type 2 diabetes in general practice reveals that non-cardiovascular comorbidities such as osteoarthritis and depression are common, and significantly more so than in people without diabetes.

Real-world study findings suggest that heart failure is associated with the greatest increase in mortality risk when compared with other cardiovascular and renal complications among people with newly diagnosed type 2 diabetes.

A study shows marked variations in cardiovascular risk burden according to age, sex, and ethnicity at the point of type 2 diabetes diagnosis, with implications for both diabetes prevention and cardiovascular risk management.

People who meet the criteria for prediabetes during the 3 years before a type 2 diabetes diagnosis have a higher burden of vascular disease than those who do not, research shows.

The results of a small randomized trial suggest exercise is more helpful than diet for combating early cardiac dysfunction associated with type 2 diabetes, although both may be beneficial.

Treatment with dapagliflozin is associated with a significant reduction in the risk for heart failure worsening or cardiovascular death in people with heart failure and reduced ejection fraction regardless of whether or not they have diabetes, shows an exploratory analysis of DAPA-HF trial data.

More than half of people with coronary artery disease have impaired glucose tolerance, yet many are unaware of this or are undertreated despite knowledge of their condition, results of the EUROASPIRE V survey show.

The benefits and harms of intensive glucose control in people with type 2 diabetes may depend on which form of haptoglobin they have, shows an analysis of the ACCORD trial.

People with type 2 diabetes and reduced kidney function in the absence of albuminuria have an increased risk for mortality and major adverse cardiovascular events, despite a low risk for end-stage renal disease, research shows.

Dapagliflozin treatment significantly improves self-reported symptoms, physical function, and quality of life in people who have heart failure with reduced ejection fraction, report the DAPA-HF investigators.

Mikhail Kosiborod outlines the findings from the DEFINE-HF trial, and discusses the possible reasons why dapagliflozin had an impact on one primary endpoint but not the other (5:48).

Lars Rydén discusses how the results of the DAPA-HF and DEFINE-HF trials will impact treatment decisions for patients with heart failure (6:38).

John McMurray talks about the results of the DAPA-HF trial, discussing whether the benefits of dapagliflozin for patients with heart failure could be extended to other SGLT2 inhibitors, and the next steps for research (3:29).

Ten-year results from the Beijing Community Diabetes Study indicate that collaborative care delivered by primary care providers and specialists may result in sustained improvements in cardiovascular risk factor control among people with type 2 diabetes.

People with type 2 diabetes and obesity who undergo metabolic surgery have a significantly lower risk for major adverse cardiovascular events than those who do not receive surgery, observational study data show.

The addition of dapagliflozin to standard treatment may be beneficial for patients with established heart failure and reduced ejection fraction, indicate findings from the DAPA-HF trial.

Treatment with glucagon-like peptide receptor agonists reduces the risk for major adverse cardiovascular events among people with type 2 diabetes, indicate findings from a large meta-analysis.

Findings from the SAVOR-TIMI 53 trial suggest that metformin treatment reduces cardiovascular and all-cause mortality but not nonfatal cardiovascular disease events, but a meta-analysis points to wider benefits.